之江生物 (688317.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

60.9x

Market Cap

CNY 3.26B

MomentumView details →

1D Return

−2.99%

YTD Return

—

RSI (14)

46.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

60.9x

Market Cap

CNY 3.26B

RSI (14)

46.9

MomentumView details →

1D Return

−2.99%

YTD Return

—

ProfitabilityView details →

Gross Margin

65.11%

Net Margin

−37.08%

EBITDA Margin

14.98%

ROE (TTM)

−1.33%

ROA (TTM)

−1.18%

Asset Turnover

0.03x

GrowthView details →

Revenue YoY

−25.98%

EPS YoY

+71.85%

FCF YoY

−28.04%

Revenue CAGR 3Y

−62.28%

EPS CAGR 3Y

+71.64%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

25.19x

Quick Ratio

24.76x

Div Yield

—

Div Rate

—

Div Growth 1Y

−90.83%

Financials snapshotView financials →

Revenue (TTM)

118.10M

Net Income (TTM)

−43.79M

Op. CF (TTM)

61.19M

Latest newsMore news →

ZhiJiang Bio announced its 2026 first-half results, reporting a net loss of 40.5894 million yuan, compared with a loss of 9.851 million yuan in the same period of 2025.9d ago

Zhi Jiang Bio announced that its monkeypox virus nucleic acid detection kit (fluorescent PCR method) obtained a Class III medical device registration certificate from China's NMPA, valid from August 17, 2026 to August 16, 2031, allowing use in China and other countries recognizing NMPA.17d ago

Similar companies

申联生物688098.SH Laekna, Inc.02105.HK HJ Science Co., Ltd.06132.HK Structure Therapeutics Inc.GPCR 南模生物688265.SH Celldex Therapeutics, Inc.CLDX Find similar companies →

Latest newsMore news →

ZhiJiang Bio announced its 2026 first-half results, reporting a net loss of 40.5894 million yuan, compared with a loss of 9.851 million yuan in the same period of 2025.9d ago Zhi Jiang Bio announced that its monkeypox virus nucleic acid detection kit (fluorescent PCR method) obtained a Class III medical device registration certificate from China's NMPA, valid from August 17, 2026 to August 16, 2031, allowing use in China and other countries recognizing NMPA.17d ago